autotaxin (ENPP2)
Assets acting on this target.
- Class
- autotaxin inhibitor
- Notes
- mechanism wave 2026-08-24 (PubMed co-occurrence, 2 article(s)); source: https://pubmed.ncbi.nlm.nih.gov/36640760/
Assets acting on this target.
1 of 1 assets (1 discontinued)
| Drug | Owner | Mechanism | Indication | Reached | Why it stopped | Source |
|---|---|---|---|---|---|---|
| Ziritaxestat | Lakefront Biotherapeutics NV | autotaxin (ENPP2) | Idiopathic Pulmonary Fibrosis | Ph 3 | These two Phase 3 IPF trials (ISABELA 1/2, NCT03733444 and NCT03711162) were both TERMINATED in 2020 after an independent data-monitoring committee found an unfavourable benefit-risk profile for GLPG1690 in IPF. | source ↗ |